Literature DB >> 28123887

CD4+CD25hiCD127- Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.

Fabio Morandi1, Sarah Pozzi2, Sebastiano Barco3, Giuliana Cangemi3, Loredana Amoroso4, Barbara Carlini1, Vito Pistoia5, Maria Valeria Corrias1.   

Abstract

Metastatic spread in the bone marrow (BM) at diagnosis is the worst prognostic factor for neuroblastoma (NB) patients. Here, we analyzed the presence of two immunosuppressive cell subsets, CD4+CD25hiCD127- regulatory T (Treg) cells and CD4+CD45R0+CD49b+LAG3+ type 1 regulatory (Tr1) cells, in BM and peripheral blood (PB) samples from NB patients and controls. Frequency of both regulatory cell subsets was lower in BM and PB samples from NB patients than in respective healthy controls. No correlation was found between the frequency of Treg and Tr1 cells and prognostic factors at diagnosis, such as age and stage. Only MYCN amplification correlated to a higher number of Treg in BM and of Tr1 in PB. These findings suggested an altered trafficking of regulatory T cells in NB, but delineated a limited role of these subsets in BM microenvironment and/or periphery in NB. These observations should be considered designing immunotherapeutic approaches for metastatic NB.

Entities:  

Keywords:  Neuroblastoma; Tr1; Treg; prognostic factors

Year:  2016        PMID: 28123887      PMCID: PMC5214984          DOI: 10.1080/2162402X.2016.1249553

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  24 in total

1.  Germline PHOX2B mutation in hereditary neuroblastoma.

Authors:  Yael P Mosse; Marci Laudenslager; Deepa Khazi; Alex J Carlisle; Cynthia L Winter; Eric Rappaport; John M Maris
Journal:  Am J Hum Genet       Date:  2004-10       Impact factor: 11.025

2.  Circulating T-regulatory cells in neuroblastoma: a pilot prospective study.

Authors:  Tvsvgk Tilak; Surender Sherawat; Sandeep Agarwala; Ritu Gupta; Sreenivas Vishnubhatla; Sameer Bakhshi
Journal:  Pediatr Hematol Oncol       Date:  2014-03-31       Impact factor: 1.969

3.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

4.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

Review 5.  Evaluation of bone marrow as a metastatic site of human neuroblastoma.

Authors:  Fabio Morandi; Maria Valeria Corrias; Vito Pistoia
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

6.  A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.

Authors:  Peter Brinkrolf; Silke Landmeier; Bianca Altvater; Christiane Chen; Sibylle Pscherer; Annegret Rosemann; Andreas Ranft; Uta Dirksen; Heribert Juergens; Claudia Rossig
Journal:  Int J Cancer       Date:  2009-08-15       Impact factor: 7.396

Review 7.  Differences in tumor regulatory T-cell localization and activation status impact patient outcome.

Authors:  Christine Ménétrier-Caux; Michael Gobert; Christophe Caux
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

8.  Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals.

Authors:  Linhua Zou; Brian Barnett; Hana Safah; Vincent F Larussa; Melina Evdemon-Hogan; Peter Mottram; Shuang Wei; Odile David; Tyler J Curiel; Weiping Zou
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

9.  IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.

Authors:  Fabio Morandi; Michela Croce; Giuliana Cangemi; Sebastiano Barco; Valentina Rigo; Barbara Carlini; Loredana Amoroso; Vito Pistoia; Silvano Ferrini; Maria Valeria Corrias
Journal:  J Immunol Res       Date:  2015-04-19       Impact factor: 4.818

10.  The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells.

Authors:  Silvia Gregori; Kevin S Goudy; Maria Grazia Roncarolo
Journal:  Front Immunol       Date:  2012-02-29       Impact factor: 7.561

View more
  7 in total

Review 1.  Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

Authors:  Thitinee Vanichapol; Somchai Chutipongtanate; Usanarat Anurathapan; Suradej Hongeng
Journal:  Biomed Res Int       Date:  2018-02-25       Impact factor: 3.411

Review 2.  Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions.

Authors:  Shweta Joshi
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

Review 3.  Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes.

Authors:  Claudia Cocco; Fabio Morandi; Irma Airoldi
Journal:  Cells       Date:  2021-04-17       Impact factor: 6.600

Review 4.  Bone Marrow Environment in Metastatic Neuroblastoma.

Authors:  Chiara Brignole; Fabio Pastorino; Patrizia Perri; Loredana Amoroso; Veronica Bensa; Enzo Calarco; Mirco Ponzoni; Maria Valeria Corrias
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

5.  Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.

Authors:  Valentina Rigo; Laura Emionite; Antonio Daga; Simonetta Astigiano; Maria Valeria Corrias; Concetta Quintarelli; Franco Locatelli; Silvano Ferrini; Michela Croce
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

Review 6.  "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.

Authors:  Kevin X Liu; Shweta Joshi
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

Review 7.  The Tumor Microenvironment in Neuroblastoma: New Players, New Mechanisms of Interaction and New Perspectives.

Authors:  Laurence Blavier; Ren-Ming Yang; Yves A DeClerck
Journal:  Cancers (Basel)       Date:  2020-10-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.